Related Experiment Video

Updated: Jul 19, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

[Why it is necessary to reduce heart rate in the treatment of stable angina?]

V I Makolkin, F N Ziabrev

    Kardiologiia
    |October 19, 2006
    PubMed

    Insights

    Elevated heart rate (HR) is a significant risk factor for cardiovascular disease. New heart rate-reducing therapy, ivabradine, effectively treats stable angina by reducing ischemia and symptoms.

    Area of Science:

    • Cardiology
    • Pharmacology

    Context:

    • Stable angina is a common cardiovascular condition.
    • Elevated heart rate (HR) is a recognized risk factor for cardiovascular morbidity and mortality.
    • Current treatment guidelines emphasize HR reduction as a cornerstone of stable angina management.

    Purpose:

    • To review the role of HR as a risk factor in cardiovascular diseases, particularly stable angina.
    • To highlight the therapeutic potential of novel HR-reducing agents.

    Summary:

    • Epidemiological data confirm elevated HR as a risk factor for cardiovascular diseases.
    • Ivabradine, a selective I(f) current inhibitor, is a novel therapeutic option for stable angina.
    • Clinical studies show ivabradine possesses significant anti-ischemic and antianginal efficacy.

    Impact:

    • Ivabradine offers a new therapeutic avenue for managing stable angina.
    • Targeting HR with ivabradine can improve clinical outcomes in patients with stable angina.
    • This reinforces the importance of HR management in cardiovascular disease prevention and treatment.

    More Related Videos

    A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

    A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

    Published on: December 28, 2012

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    Related Concept Videos

    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Angina V: Nursing Management01:20

    Angina V: Nursing Management

    Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Angina II: Classification01:27

    Angina II: Classification

    Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Decreased pulse rate01:14

    Decreased pulse rate

    Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
    There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...